Steven J. Burakoff

From Wikipedia, the free encyclopedia

Steven J. Burakoff, MD, is a cancer specialist and the author of both Therepeutic Immunology (2001) and Graft-Vs.-Host Disease: Immunology, Pathophysiology, and Treatment (1990).

Contents

[edit] Biography

Dr. Burakoff is the Director of the Mount Sinai Medical Center’s Cancer Institute, which was created in 2007 to focus on translational medicine.

Before joining Mount Sinai, he was recruited by NYU to revitalize the research and treatment mission of NYU's Cancer Institute, which during his tenure experienced a 31 percent growth and a 50 percent increase in NCI funding.[1]

He completed a residency in medicine at New York Hospital-Cornell Medical Center and pursued a fellowships in immunology at both Rockefeller University and Harvard Medical School.

[edit] Awards

  • Harvard Medical School Excellence in Mentoring Award

[edit] Appointments and Positions

  • Director of The Mount Sinai Medical Center’s (Mount Sinai Hospital homepage) Cancer Institute
  • Formerly Laura and Isaac Perlmutter Professor, New York University School of Medicine
  • Past Director, New York University Cancer Institute
  • Past Director, Skirball Institute of Biomolecular Medicine, New York University School of Medicine[2]
  • Past Chair of Pediatric Oncology at the Dana-Farber Cancer Institute
  • Formerly Margaret M. Dyson Professor of Pediatrics at the Harvard Medical School
  • Former Ted Williams Senior Investigator at the Dana-Farber Cancer Institute
  • Former Member, Board of Trustees of the Dana-Farber Cancer Institute
  • Board of Directors, Pharmacopeia Drug Discovery, Inc.[3]

[edit] Education

[edit] Other Publications

A partial list of recent publications:

  • Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway. Sawasdikosol S, Pyarajan S, Alzabin S, Matejovic G, Burakoff SJ. The journal of biological chemistry, 2007
  • From bytes to bedside: data integration and computational biology for translational cancer research. Mathew JP, Taylor BS, Bader GD, Pyarajan S, Antoniotti M, Chinnaiyan AM, Sander C, Burakoff SJ, Mishra B. PLoS computational biology, 2007
  • A CD8/Lck transgene is able to drive thymocyte differentiation. Fragoso RC, Pyarajan S, Irie HY, Burakoff SJ. Journal of immunology, 2006
  • HIV Nef-mediated CD4 down-regulation is adaptor protein complex 2 dependent. Jin YJ, Cai CY, Zhang X, Zhang HT, Hirst JA, Burakoff SJ. Journal of immunology, 2005
  • CD4 phosphorylation partially reverses Nef down-regulation of CD4. Jin YJ, Zhang X, Boursiquot JG, Burakoff SJ. Journal of immunology, 2004
  • Nicotine activates nuclear factor of activated T cells c2 (NFATc2) and prevents cell cycle entry in T cells. Frazer-Abel AA, Baksh S, Fosmire SP, Willis D, Pierce AM, Meylemans H, Linthicum DS, Burakoff SJ, Coons T, Bellgrau D, Modiano JF. The journal of pharmacology and experimental theraputics, 2004
  • SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness. Friedman JS, Lopez MF, Fleming MD, Rivera A, Martin FM, Welsh ML, Boyd A, Doctrow SR, Burakoff SJ. Blood, 2004
  • Fratricide of CD8+ cytotoxic T lymphocytes is dependent on cellular activation and perforin-mediated killing. Su MW, Pyarajan S, Chang JH, Yu CL, Jin YJ, Stierhof YD, Walden P, Burakoff SJ. European journal of immunology, 2004
  • Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwitz D, Boyd A, Kupper TS, Burakoff SJ. Journal of the American society of blood and marrow transplantation, 2004
  • Rapamycin-resistant proliferation of CD8+ T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity. Slavik JM, Lim DG, Burakoff SJ, Hafler DA., Journal of biological chemistry, 2004

[edit] References

[edit] External Links